Somatostatin Analog. Octreotide 0.1 mg/ml, 0.5 mg/ml. AMP.Sol. for inj/inf. 10X 1 ml for SC/IV
Acromegaly Initially 0.05 to 0.1 mg by s.c.inject. every 8 or 12 hours. Dosage adjustm. should be based on monthly assessment of GH and IGF-1 levels (target: GH<2.5 ng/mL; IGF-1 within normal range) and clin. sympt., and on tolerability. In most pts, the optimal dly dose will be 0.3 mg. A max. dose of 1.5 mg /d should not be exceeded. For pts on a stable dose, assessment of GH should be made every 6 months. If no relevant reduct. in GH levels and no improvement in clin. sympt. have been achieved within 3 months of tmt. with this drug, ther. should be discontinued.
Gastro-entero-pancreatic endocrine tumours Initially 0.05 mg once or twice/d by s.c. inject. Depending on clin. respon., effect on levels of tumour-produced hnes. (in cases of carcinoid tumours, on the urinary excretion of 5-hydroxyindole acetic acid), and on tolerability, dosage can be gradually incr. to 0.1 to 0.2 mg 3 times/d. Under exceptional circumstances, higher doses may be req. Maint. doses have to be adjusted individually. In carcinoid tumours, if there is no beneficial respon. within 1 week of tmt. with this drug at the max toler. dose, ther. should not be continued.
Complications following pancreatic surgery 0.1 mg 3 times/d by s.c. inj. for 7 consecutive days, starting on the day of operation at least 1 hour before laparotomy.
Bleeding gastro-oesophageal varices 25 micrograms/h for 5 d by continuous i.v. infusion. This drug can be used in dilution with physiological saline. In cirrhotic pts with bleeding gastro-oesophageal varices, this drug has been well tolerat. at continuous i.v. doses of up to 50 micrograms/h for 5 days.
Prevention of complicat. following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. This treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. This drug is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
C/I: Hypersens.
Hematinic. Iron (as Ferric carboxymaltose) 50 mg/ml. Dispers. for inf. VIAL: 1/2/5 X 2 ml/10 ml; 1 X 20 ml
Admin. 1000 mg once/w.
Tmt. of iron defic. when oral iron preparat. are ineffective or cannot be used. The diagnosis must be based on lab. tests
C/I: Hypersens. incl. to other inject. iron preparations. Anemia not caused by iron defic. Iron excess or hereditary disorder in iron utilization.
Anticholinergic agent. Glycopyrronium Bromide 0.2 mg/ml. Bottle.Oral sol. 150 ml X 0.2 mg/ml
Recommended for short-term intermittent use.
Dosage must be meas. and admin. with the grad. syringe incl. in the pack.
Dosing sched. is based on the BW with the initial dosing of 0.02 mg/kg to be given three times dly and titrate in increm. of 0.02 mg/kg every 5-7 days based on therap. resp. and adverse reactions. The max. recomm. dosage is 0.1 mg/kg three times dly. not to exceed 1.5-3 mg per dose based upon weight.
See prescribing information for full details
Symptom. tmt. of sev. sialorrhoea (chron. pathol. drooling) in child and adolesc. aged 3 years and older with chron. neurolog. dis.
C/I: Hypersens. / Angle-closure glaucoma/
Myasthenia gravis (large doses of quatern. ammonium compounds have been shown to antagonise end plate nicotinic receptors)/
Pyloric stenosis/Paralytic ileus/
Prostatic enlargement/ Urin. retent./
Sev. renal impairm. (eGFR <30 ml/min/1.73m2, incl. those req. dialysis/
Intestinal obstruct./ Pregnancy and breast-feeding.
Potassium chloride solid oral dose prod./Anticholinergic medic.
Kappa Opioid Receptor Agonist. Difelikefalin 50 mcg/ml. Sol. for IV inj. 3/12 X 1 ml
This prod. should be restricted for in-centre haemodialysis use only.
To be admin. 3 times per week by IV bolus inj. into the venous line of the dialysis circuit at the end of haemodialysis during rinse-back or after rinse-back.
Recomm. dose of difelikefalin is 0.5 microg/kg dry BW (i.e., the target postdialysis weight). The total dose volume (mL) required from the vial should be calculated as follows: 0.01 × dry body weight (kg), rounded to the nearest tenth (0.1 mL). For pts. with a dry BW equal to or above 195 kg the recomm. dose is 100 microgr (2 mL). See prescribing info.
Tmt. of moderate-to-severe pruritus associated with chronic kidney dis. in adult pts. on haemodialysis
C/I: Hypersens.
Insulin-Like Growth Factor-1 Receptor Antagonist. Teprotumumab 500 mg/vial. VIAL 1X 500 mg, powder for concen. for sol. for inf.
Assess pts. for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with this drug. Ensure pts. with hyperglycemia or pre-existing diabetes are under appropriate glycemic ctrol. before and while receiving this drug.
Assess pts.’ hearing before, during, and after tmt. with this drug and consider the benefit-risk of tmt.
The recommended dose is an IV infusion of 10 mg/kg for the initial dose followed by an IV infusion of 20 mg/kg every three weeks for 7 additional infusions.
Tmt. of moderate to severe Thyroid Eye Disease regardless of activity and duration
C/I: Hypersens
Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml. Sol. for inject.: 1 X 0.23 ml /vial
Dose in adults : 0.5 mg given as a single intravitreal inject. This corresponds to an inject. vol. of 0.05 ml. Interval between 2 doses injected into the same eye should be at least 4 weeks. See lit.
Pts. with neovascular (wet) age-related macular degeneration (AMD)
Adult pts. with visual impairment due to diabetic macular oedema (DME)
Visual impairment due to macular oedema second. to retinal vein occlusion (RVO)
Visual impairment due to choroidal neovascularization (CNV)
Proliferative diabetic retinopathy (PDR)
C/I: Hypersens.
Active or suspected ocular or periocular infections.
Active severe intraocular inflammation.
אפיקסבן בטיפול מורחב ובמינון מופחת עבור תרומבואמבוליזם ורידי הקשור לסרטן
הידרוקסיכלורוקין למניעת התקדמות מלופוס עורית ללופוס מערכתית
FRO – כלי חדש לחיזוי אישי של סיבוכי קוצר ראייה
תוצאי טיפול במגיבי-על לטיפולים ביולוגיים בפסוריאזיס
שינה, מקצב צירקדי וכאב בנשים עם הפרעות במפרק הלסת ואינסומניה
יעילות ובטיחות ג׳ל סופירוניום בטיפול בהזעת יתר בבית השחי
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
CGRP, Human Monoclonal Antibody. Erenumab 70 mg, 140 mg. PRE-FILL. SYR (sol. for S.C. inj.): 1
PRE- FIL. PEN (sol. for S.C. inj.): 1
Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with erenumab.
The recomm. dose is 70 mg erenumab every 4 wks. Some pts. may benefit from a dose of 140 mg every 4 wks.
Each 140 mg dose is given as two S.C. inj. of 70 mg. See lit.
Tmt. should be initiat. by physicians experienced in the diagnosis and tmt. of migraine.
C/I: Hypersens.
Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg. PRE-FILL. SYR. (Sol.for S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1st dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
month.
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.
melatonin receptor agonists. Melatonin 1 mg, 5 mg. PR Tabs: 60 X 1 mg, 30 X 5mg. Recommend. Start. dose 2 mg. If inadeq. response observ., dose should be incr. to 5 mg, with a max. dose of 10 mg.
Drug should be taken once dly., 0.5-1 hr. before bedtime, with or after food.
Tmt. of insomnia in child. and adolesc. aged 2-18 with ASD and / or Smith-Magenis syndr., where sleep hygiene meas. have been insuff.
C/I: Hypersens.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
Phosphodiesterase-5 Enzyme Inhibitor. Sildenafil 25 mg. Susp. for oral spray 20 ml. Each actuat. delivers 0.5 ml susp., contain. 12.5 mg sildenafil
Dose is 2 mL (4 act.), equiv. to 50 mg of sildenafil taken as needed, approx. one hour before sexual activ. Based on effic. and tolerab., dose may be incr. to 4 mL (8 act.), equiv. to 100 mg, or decr. to 1 mL (2 act.), equiv. to 25 mg of sildenafil. Max. dose is 4 mL (8 act.), equiv. to 100 mg of sildenafil. Max. dosing freq. is 1/d.
In adult men with erectile dysfunction.
C/I: Hypersens. Co-administr. with nitric oxide donors (such as amyl nitrite) or nitrates in any form. Co-administr. with guanylate cyclase stimul., such as riociguat, as it may lead to symptom. Hypotension. Not to be used in men for whom sexual act. is inadvisable (e.g. pts. with sev. CV disord. such as unstable angina or sev. HF). Contraindic. in ptts. who have loss of vision in one eye due to non-arteritic anterior ischaemic optic neuropathy (NAION). Safety has not been studied in the follow. sub-groups of pts. and use is contraindic. in these pts: sev. hepatic impairm., hypotension (blood pressure <90/50 mmHg), recent hist. of stroke or MI and known heredit. degenerat. retinal disord. such as retinitis pigmentosa.
NSAID. Etoricoxib 60, 90 mg. TABS.: 7,10,14,×60,90 mg .
Osteoarthrit.: 60 mg ×1/d
RA: 60 mg×1/d, can be incr. to a max. of 90 mg×1/d, if necessary.
Ankylos. spondylit.: 60 mg ×1/d, can be incr. to a max. of 90 mg ×1/d, if necessary.
Acute pain condit.: Etoricoxib should be used only for the acute painful period.
Postoperat. dental surg. pain: 90 mg ×1/d, limited to a max. of 3 tmt. d.
60 mg tabs.: indic. for the symptom. relief of OA, RA and ankylos. spondylitis.
90 mg tabs.: indic. for the symptom. relief of RA and ankylos. spondylitis. For the short-term tmt. of moder. pain assoc. with dental surg.
C/I: Hypersens. Hypersens. to NSAIDs, includ. aspirin and COX-2 inhib.
Pts. with peptic ulcer, bleed. or intest. bleed.
Pts. with severe hep. dis. Pts. with a severe renal dis. Preg. Lact. Pts. under 16 yrs. of age. Pts. with IBD, Crohn’s dis., ulcerat. colitis. Pts. with uncontrolled hypertension. Pts. with HF (moder./severe). Pts. with ischem. heart dis./peripher. vasc. dis. (e.g. DVT). Pts. with any kind of stroke, (TIA). Pts. with history of MI.
SNRI. Duloxetine 30 , 60 mg. CAPS.:30. For diabet. peripher. neuropath. pain: The usual dose is 60 mg ×1/d.
For chron. musculoskel. pain and general. anxiety disord.: For most pts.
60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of
60 mg ×1/d.
For depression: Most pts. will receive 60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d
Elderly – The init. dose of 30 mg ×1/d for two wks., and only then consider incr. the dose to 60 mg ×1/d.
Fibromyalgia: The init. dose of Dulox Teva is 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d. In most cases, the effect of medication ther. with Dulox Teva is noticeab. after 2-4 wks. of tmt.
See lit.
Tmt. of major depressive episodes.
Managem. of neuropath.pain associat. with diabet. peripher. neuropathy.
Tmt. of generaliz. anxiety disord. (GAD).
Manag. of fibromyalgia.
Manag. of chron. muscoskel. pain when other therapies have failed or are
contraindic. This has been establish. in studies in pts. with chron. low back pain (CLBP) and chron. pain due to osteoarthritis.
C/I: Hypersens.
Pts. with hep. dis.
Pts. with severe ren. dis..
Concom. use with MAOI includ. IV methylene blue and the antibiot.linezolid. MAOI should be discount. 14 d. before init.of the tmt. with duloxetine.
Initiat. of MAOI should be start. at least 5 d. after discount. of the tmt. with duloxetine.
Concom. use with thioridazine
